[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100554382":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":35,"collaborators":7,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":39,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":7,"studyType":51,"phases":7,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},{"fullName":5,"class":6},"University Hospital, Strasbourg, France","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Sarah BAER, MD","CONTACT","33 3 88 12 63 98","sarah.baer@chru-strasbourg.fr",[15],{"facility":16,"status":17,"city":18,"state":7,"zip":19,"country":20,"countryCode":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":28},"Service pédiatrie 1 - CHU de Strasbourg - France","RECRUITING","Strasbourg","67091","France","FR",{"type":23,"coordinates":24},"Point",[25,26],7.74553,48.58392,{"lat":26,"lon":25},[29,30,32],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"name":10,"role":31,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"name":33,"role":34,"phone":7,"phoneExt":7,"email":7},"Armelle HORNARD, MD","SUB_INVESTIGATOR",{"type":36,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100554382","the-new-place-of-levetiracetam-in-the-management-of-status-epilepticus-in-children-100554382",false,"NCT06498362","The \"New\" Place of LEVETIRACETAM in the Management of Status Epilepticus in Children","The \"New\" Place of LEVETIRACETAM in the Management of Status Epilepticus in Children: Multicenter Retrospective Study on 151 Children Over Three Months Old","LEVET","Inclusion Criteria:\n\n* Minor patient aged 3 months to 17 years\n* 2nd line treatment with LEVETIRACETAM or PHENYTOIN after failure of benzodiazepines\n* Supported in one of the participating centers during the period from November 1, 2019 to May 31, 2023\n* Subject or parents who have not expressed, after information, their opposition to the reuse of their data for the purposes of this research.\n\nExclusion Criteria:\n\n* Patient or parents having expressed their opposition to participating in the study.","ALL","3 Months","17 Years",{"count":49,"type":50},151,"ESTIMATED","OBSERVATIONAL","Status epilepticus is the leading neurological emergency in children, with mortality 2-7% and significant morbidity (10-20%). It is defined as the occurrence of a crisis lasting more than 5 minutes and requiring the implementation of treatment to stop it and thus limit the immediate and long-term consequences.\n\nThe research hypothesis is that LEVETIRACETAM is non-inferior to PHENYTOIN in terms of cessation and absence of recurrence of status epilepticus, with better clinical tolerance in children from 3 months to 17 years old, with or without epileptic disease, with or without a history of status epilepticus",[54],"Epilepsy in Children",[56,54],"Epilepsy","2024-07-04",{"date":59,"type":60},"2024-07-12","ACTUAL",{"date":62,"type":60},"2023-11-16",{"date":64,"type":50},"2025-05-16",{"name":5,"class":6},1]